Chimeric Therapeutics is trading at A$0.04, down 8.3% today, as the stock faces a sharp pullback driven by broader weakness across biotechnology names and profit-taking.
- The decline appears to be linked to risk-off sentiment in the wider biotech sector rather than a shift in company-specific fundamentals.
- The downward move comes despite the company recently reporting encouraging interim clinical trial data.